Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Osterborg, A.
Right arrow Articles by Mellstedt, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Osterborg, A.
Right arrow Articles by Mellstedt, H.

Journal of Clinical Oncology, Vol 15, 1567-1574, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

A Osterborg, MJ Dyer, D Bunjes, GA Pangalis, Y Bastion, D Catovsky and H Mellstedt
Department of Oncology (Radiumhemmet), Karolinska Hospital, Stockholm, Sweden. aob@rah.Ks.se

PURPOSE: CAMPATH-1H is a human immunoglobulin G1 (IgG1) anti-CD52 monoclonal antibody (MAb) that binds to nearly all B- and T-cell lymphomas and leukemias. We report the results of a multicenter phase II trial that used CAMPATH-1H in previously chemotherapy-treated patients with chronic lymphocytic leukemia (CLL). MATERIALS AND METHODS: Twenty-nine patients who had relapsed after an initial response (n = 8) or were refractory (n = 21) to chemotherapy were treated with CAMPATH-1H administered as a 30-mg 2-hour intravenous (IV) infusion thrice weekly for a maximum period of 12 weeks. RESULTS: Eleven patients (38%) achieved a partial remission (PR) and one (4%) a complete remission (CR) (response rate, 42%; 95% confidence interval [CI], 23% to 61%). Three of eight patients (38%) with a relapse and nine of 21 refractory patients (43%) responded to CAMPATH-1H therapy. CLL cells were rapidly eliminated from blood in 28 of 29 patients (97%). CR in the bone marrow was obtained in 36% and splenomegaly resolved completely in 32%. Lymphadenopathy was normalized in only two patients (7%). The median response duration was 12 months (range, 6 to 25+). World Health Organization (WHO) grade IV neutropenia and thrombocytopenia developed in three (10%) and two patients (7%), respectively. Neutropenia and thrombocytopenia recovered in most responding patients during continued CAMPATH-1H treatment. Lymphopenia (< 0.5 x 10(9)/L) occurred in all patients. Two patients had opportunistic infections and four had bacterial septicemia. CONCLUSION: CAMPATH-1H had significant activity in patients with advanced and chemotherapy-resistant CLL. The most pronounced effects were noted in blood, bone marrow, and spleen. Preferential clearance of blood may allow harvesting of uncontaminated blood stem cells for use in high- dose chemotherapy protocols.


This article has been cited by other articles:


Home page
 haematolHome page
T. Elter, J. Kilp, P. Borchmann, H. Schulz, M. Hallek, and A. Engert
Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia
Haematologica, January 1, 2009; 94(1): 150 - 152.
[Full Text] [PDF]

Home page
 BloodHome page
S. O'Brien, F. Ravandi, T. Riehl, W. Wierda, X. Huang, J. Tarrand, B. O'Neal, H. Kantarjian, and M. Keating
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy
Blood, February 15, 2008; 111(4): 1816 - 1819.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Demko, J. Summers, P. Keegan, and R. Pazdur
FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia
Oncologist, February 1, 2008; 13(2): 167 - 174.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Baskar, K. Y. Kwong, T. Hofer, J. M. Levy, M. G. Kennedy, E. Lee, L. M. Staudt, W. H. Wilson, A. Wiestner, and C. Rader
Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia
Clin. Cancer Res., January 15, 2008; 14(2): 396 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Lapalombella, X. Zhao, G. Triantafillou, B. Yu, Y. Jin, G. Lozanski, C. Cheney, N. Heerema, D. Jarjoura, A. Lehman, et al.
A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents
Clin. Cancer Res., January 15, 2008; 14(2): 569 - 578.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
W. G. Wierda
Treatments for Patients with Chronic Lymphocytic Leukemia
ASCO Educational Book, January 1, 2008; 2008(1): 297 - 305.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Flynn and J. C. Byrd
Have We Forgotten the Purpose of Phase III Studies?
J. Clin. Oncol., December 10, 2007; 25(35): 5553 - 5555.
[Full Text] [PDF]

Home page
 JCOHome page
P. Sabbatini and K. Odunsi
Immunologic Approaches to Ovarian Cancer Treatment
J. Clin. Oncol., July 10, 2007; 25(20): 2884 - 2893.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Carlo-Stella, A. Guidetti, M. Di Nicola, C. Lavazza, L. Cleris, D. Sia, P. Longoni, M. Milanesi, M. Magni, Z. Nagy, et al.
IFN-{gamma} Enhances the Antimyeloma Activity of the Fully Human Anti-Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3
Cancer Res., April 1, 2007; 67(7): 3269 - 3275.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. J. Rodig, J. S. Abramson, G. S. Pinkus, S. P. Treon, D. M. Dorfman, H. Y. Dong, M. A. Shipp, and J. L. Kutok
Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H)
Clin. Cancer Res., December 1, 2006; 12(23): 7174 - 7179.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, et al.
T lymphocytes redirected against the {kappa} light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells
Blood, December 1, 2006; 108(12): 3890 - 3897.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. E. Williams, J. J. Densmore, A. W. Pawluczkowycz, P. V. Beum, A. D. Kennedy, M. A. Lindorfer, S. H. Hamil, J. C. Eggleton, and R. P. Taylor
Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia
J. Immunol., November 15, 2006; 177(10): 7435 - 7443.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Montserrat, C. Moreno, J. Esteve, A. Urbano-Ispizua, E. Gine, and F. Bosch
How I treat refractory CLL
Blood, February 15, 2006; 107(4): 1276 - 1283.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Carlo-Stella, M. Di Nicola, M. C. Turco, L. Cleris, C. Lavazza, P. Longoni, M. Milanesi, M. Magni, M. Ammirante, A. Leone, et al.
The Anti-Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3 Activates the Mitochondrial Cell Death Pathway and Exerts a Potent Antitumor Activity in Lymphoma-Bearing Nonobese Diabetic/Severe Combined Immunodeficient Mice
Cancer Res., February 1, 2006; 66(3): 1799 - 1808.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
W. G. Wierda
Current and Investigational Therapies for Patients with CLL
Hematology, January 1, 2006; 2006(1): 285 - 294.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. T. Wong
Management of Central Nervous System Lymphomas Using Monoclonal Antibodies: Challenges and Opportunities
Clin. Cancer Res., October 1, 2005; 11(19): 7151s - 7157s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. G. Wierda, T. J. Kipps, and M. J. Keating
Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia
J. Clin. Oncol., September 10, 2005; 23(26): 6325 - 6332.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Moreton, B. Kennedy, G. Lucas, M. Leach, S. M.B. Rassam, A. Haynes, J. Tighe, D. Oscier, C. Fegan, A. Rawstron, et al.
Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival
J. Clin. Oncol., May 1, 2005; 23(13): 2971 - 2979.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Dimopoulos, R. A. Kyle, A. Anagnostopoulos, and S. P. Treon
Diagnosis and Management of Waldenstrom's Macroglobulinemia
J. Clin. Oncol., March 1, 2005; 23(7): 1564 - 1577.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
M. Hallek and On Behalf Of The German CLL Study Group
Chronic Lymphocytic Leukemia (CLL): First-Line Treatment
Hematology, January 1, 2005; 2005(1): 285 - 291.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. S. Lin, I. W. Flinn, R. Modali, T. A. Lehman, J. Webb, S. Waymer, M. E. Moran, M. S. Lucas, S. S. Farag, and J. C. Byrd
FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia
Blood, January 1, 2005; 105(1): 289 - 291.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. B. H. Bakker, S. van den Oudenrijn, A. Q. Bakker, N. Feller, M. van Meijer, J. A. Bia, M. A. C. Jongeneelen, T. J. Visser, N. Bijl, C. A. W. Geuijen, et al.
C-Type Lectin-Like Molecule-1: A Novel Myeloid Cell Surface Marker Associated with Acute Myeloid Leukemia
Cancer Res., November 15, 2004; 64(22): 8443 - 8450.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Hale, P. Rebello, L. R. Brettman, C. Fegan, B. Kennedy, E. Kimby, M. Leach, J. Lundin, H. Mellstedt, P. Moreton, et al.
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
Blood, August 15, 2004; 104(4): 948 - 955.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. C. Rawstron, B. Kennedy, P. Moreton, A. J. Dickinson, M. J. Cullen, S. J. Richards, A. S. Jack, and P. Hillmen
Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia
Blood, March 15, 2004; 103(6): 2027 - 2031.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. P. Mone, P. Huang, H. Pelicano, C. M. Cheney, J. M. Green, J. Y. Tso, A. J. Johnson, S. Jefferson, T. S. Lin, and J. C. Byrd
Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells
Blood, March 1, 2004; 103(5): 1846 - 1854.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Zhang, M. Zhang, C. K. Goldman, J. V. Ravetch, and T. A. Waldmann
Effective Therapy for a Murine Model of Adult T-Cell Leukemia with the Humanized Anti-CD52 Monoclonal Antibody, Campath-1H
Cancer Res., October 1, 2003; 63(19): 6453 - 6457.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Lundin, H. Hagberg, R. Repp, E. Cavallin-Stahl, S. Freden, G. Juliusson, E. Rosenblad, G. Tjonnfjord, T. Wiklund, and A. Osterborg
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
Blood, June 1, 2003; 101(11): 4267 - 4272.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. C. Byrd, D. M. Lucas, A. P. Mone, J. B. Kitner, J. J. Drabick, and M. R. Grever
KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis
Blood, June 1, 2003; 101(11): 4547 - 4550.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Mavromatis and B. D. Cheson
Monoclonal Antibody Therapy of Chronic Lymphocytic Leukemia
J. Clin. Oncol., May 1, 2003; 21(9): 1874 - 1881.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
S. N. O'Brien, N. M.A. Blijlevens, T. H. Mahfouz, and E. J. Anaissie
Infections in Patients with Hematological Cancer: Recent Developments
Hematology, January 1, 2003; 2003(1): 438 - 472.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. R. Rai, C. E. Freter, R. J. Mercier, M. R. Cooper, B. S. Mitchell, E. A. Stadtmauer, P. Santabarbara, B. Wacker, and L. Brettman
Alemtuzumab in Previously Treated Chronic Lymphocytic Leukemia Patients Who Also Had Received Fludarabine
J. Clin. Oncol., September 15, 2002; 20(18): 3891 - 3897.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. G. S. Buggins, G. J. Mufti, J. Salisbury, J. Codd, N. Westwood, M. Arno, K. Fishlock, A. Pagliuca, and S. Devereux
Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab
Blood, August 13, 2002; 100(5): 1715 - 1720.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
I. Espinoza-Delgado
Cancer Vaccines
Oncologist, August 1, 2002; 7(90003): 20 - 33.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. G. Jurcic, S. M. Larson, G. Sgouros, M. R. McDevitt, R. D. Finn, C. R. Divgi, A. M. Ballangrud, K. A. Hamacher, D. Ma, J. L. Humm, et al.
Targeted alpha particle immunotherapy for myeloid leukemia
Blood, July 30, 2002; 100(4): 1233 - 1239.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Lundin, E. Kimby, M. Bjorkholm, P.-A. Broliden, F. Celsing, V. Hjalmar, L. Mollgard, P. Rebello, G. Hale, H. Waldmann, et al.
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
Blood, July 18, 2002; 100(3): 768 - 773.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Fan, S. Yano, H. Shinohara, C. Solorzano, M. Van Arsdall, C. D. Bucana, S. Pathak, E. Kruzel, R. S. Herbst, A. Onn, et al.
Targeted Therapy against Human Lung Cancer in Nude Mice by High-Affinity Recombinant Antimesothelin Single-Chain Fv Immunotoxin
Mol. Cancer Ther., June 1, 2002; 1(8): 595 - 600.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. J. Keating, I. Flinn, V. Jain, J.-L. Binet, P. Hillmen, J. Byrd, M. Albitar, L. Brettman, P. Santabarbara, B. Wacker, et al.
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
Blood, May 15, 2002; 99(10): 3554 - 3561.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
A. Countouriotis, T. B. Moore, and K. M. Sakamoto
Cell Surface Antigen and Molecular Targeting in the Treatment of Hematologic Malignancies
Stem Cells, May 1, 2002; 20(3): 215 - 229.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Kennedy, A. Rawstron, C. Carter, M. Ryan, K. Speed, G. Lucas, and P. Hillmen
Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia
Blood, March 15, 2002; 99(6): 2245 - 2247.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
E Drewe and R J Powell
Clinically useful monoclonal antibodies in treatment
J. Clin. Pathol., February 1, 2002; 55(2): 81 - 85.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Keating, B. Cazin, S. Coutre, R. Birhiray, T. Kovacsovics, W. Langer, B. Leber, T. Maughan, K. Rai, G. Tjonnfjord, et al.
Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed
J. Clin. Oncol., January 1, 2002; 20(1): 205 - 213.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. M. Vose, B. C.-H. Chiu, B. D. Cheson, J. Dancey, and J. Wright
Update on Epidemiology and Therapeutics for Non-Hodgkin's Lymphoma
Hematology, January 1, 2002; 2002(1): 241 - 262.
[Abstract] [Full Text]

Home page
 J Oncol Pharm PractHome page
H. T Wu
Alemtuzumab (Campath-1H, Campath1) for the treatment of lymphoid malignancies: chronic lymphocytic leukemia and T-cell prolymphocytic leukemia
Journal of Oncology Pharmacy Practice, December 1, 2001; 7(4): 133 - 140.
[Abstract] [PDF]

Home page
 BloodHome page
C. E. Dearden, E. Matutes, B. Cazin, G. E. Tjonnfjord, A. Parreira, B. Nomdedeu, P. Leoni, F. J. Clark, D. Radia, S. M. B. Rassam, et al.
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
Blood, September 15, 2001; 98(6): 1721 - 1726.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. C. Rawstron, B. Kennedy, P. A. S. Evans, F. E. Davies, S. J. Richards, A. P. Haynes, N. H. Russell, G. Hale, G. J. Morgan, A. S. Jack, et al.
Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy
Blood, July 1, 2001; 98(1): 29 - 35.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Granziero, P. Ghia, P. Circosta, D. Gottardi, G. Strola, M. Geuna, L. Montagna, P. Piccoli, M. Chilosi, and F. Caligaris-Cappio
Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia
Blood, May 1, 2001; 97(9): 2777 - 2783.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. C. Byrd, T. Murphy, R. S. Howard, M. S. Lucas, A. Goodrich, K. Park, M. Pearson, J. K. Waselenko, G. Ling, M. R. Grever, et al.
Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity
J. Clin. Oncol., April 15, 2001; 19(8): 2153 - 2164.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
Y. Kee Shin, E. Young Choi, S. Hyung Kim, J. Chung, D. Hyun Chung, W. Seo Park, K. Cheon Jung, H. Sik Kim, S. Park, H. Jin Kim, et al.
Expression of Leukemia-Associated Antigen, JL1, in Bone Marrow and Thymus
Am. J. Pathol., April 1, 2001; 158(4): 1473 - 1480.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. D. Hainsworth
Monoclonal Antibody Therapy in Lymphoid Malignancies
Oncologist, October 1, 2000; 5(5): 376 - 384.
[Abstract] [Full Text]

Home page
 The OncologistHome page
N. Kalil and B. D. Cheson
Chronic Lymphocytic Leukemia
Oncologist, October 1, 1999; 4(5): 352 - 369.
[Abstract] [Full Text]

Home page
 BloodHome page
U. Winkler, M. Jensen, O. Manzke, H. Schulz, V. Diehl, and A. Engert
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)
Blood, October 1, 1999; 94(7): 2217 - 2224.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. S. Chowdhury, J. L. Viner, R. Beers, and I. Pastan
Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity
PNAS, January 20, 1998; 95(2): 669 - 674.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1997 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online